Ocular Therapeutix Inc (NASDAQ:OCUL) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 15, 2016
Zacks Investment Research has downgraded Ocular Therapeutix Inc (NASDAQ:OCUL) to Hold in a statement released on 10/12/2016.
Boasting a price of $6.51, Ocular Therapeutix Inc (NASDAQ:OCUL) traded -5.96% lower on the day. With the last stock price close down -14.53% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Ocular Therapeutix Inc has recorded a 50-day average of $6.78 and a two hundred day average of $7.94. Volume of trade was up over the average, with 2,494,435 shares of OCUL changing hands over the typical 1,217,160
With a total market value of $0, Ocular Therapeutix Inc has with a one year low of $4.04 and a one year high of $17.34 .
A total of 4 equity analysts have released a ratings update on OCUL. One equity analyst rating the company a strong buy, three equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $36.75.
Brief Synopsis About Ocular Therapeutix Inc (NASDAQ:OCUL)
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company's bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company's product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company's lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug. The OTX-TP product candidate incorporates the prostaglandin analog travoprost as an active pharmaceutical ingredient in its punctum plug.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.